Literature DB >> 2138655

The iC3b receptor on Candida albicans: subcellular localization and modulation of receptor expression by glucose.

M K Hostetter1, J S Lorenz, L Preus, K E Kendrick.   

Abstract

Patient isolates of Candida albicans from blood, urine, or mucosal sites express a surface receptor for C3 fragment iC3b that is recognized by monoclonal antibodies (MAb) directed against alpha-chain epitopes of the neutrophil iC3b receptor, also known as the type 3 complement receptor (CR3) or CD11b/CD18. Because 60% of these patients were hyperglycemic, the effect of glucose on receptor expression was investigated. As assessed by flow cytometry, yeasts grown in 20 mM D-glucose exhibited a four- to six-fold increase in receptor expression compared with yeasts grown in 20 mM L-glutamate. Receptor expression increased as glucose concentration rose from 0 to 20 mM (equivalent to plasma glucose concentrations of 0-360 mg/dl). Augmentation of receptor expression by growth in glucose led to significant inhibition of phagocytosis compared with that of organisms grown in equimolar L-glutamate. SDS-PAGE, Western blotting, and immunodetection of extracts of yeast cell wall, membrane, and cytosol disclosed a protein of 165 kDa in membrane and cytosolic extracts, consistent with the published Mr of the alpha-chain of neutrophil CR3. These studies provide a mechanism to explain the predilection of C. albicans to infect the hyperglycemic host.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2138655     DOI: 10.1093/infdis/161.4.761

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  35 in total

1.  Surface epithelium related activation of complement differs in Crohn's disease and ulcerative colitis.

Authors:  T S Halstensen; T E Mollnes; P Garred; O Fausa; P Brandtzaeg
Journal:  Gut       Date:  1992-07       Impact factor: 23.059

Review 2.  Candida albicans-endothelial cell interactions: a key step in the pathogenesis of systemic candidiasis.

Authors:  Sarah E W Grubb; Craig Murdoch; Peter E Sudbery; Stephen P Saville; Jose L Lopez-Ribot; Martin H Thornhill
Journal:  Infect Immun       Date:  2008-06-23       Impact factor: 3.441

3.  Effect of an arginine-glycine-aspartic acid-containing peptide on hematogenous candidal infections in rabbits.

Authors:  S A Klotz; R L Smith; B W Stewart
Journal:  Antimicrob Agents Chemother       Date:  1992-01       Impact factor: 5.191

Review 4.  Antifungal agents: chemotherapeutic targets and immunologic strategies.

Authors:  N H Georgopapadakou; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  1996-02       Impact factor: 5.191

Review 5.  Cell wall and secreted proteins of Candida albicans: identification, function, and expression.

Authors:  W L Chaffin; J L López-Ribot; M Casanova; D Gozalbo; J P Martínez
Journal:  Microbiol Mol Biol Rev       Date:  1998-03       Impact factor: 11.056

Review 6.  Clinical microbiology of bacterial and fungal sepsis in very-low-birth-weight infants.

Authors:  David Kaufman; Karen D Fairchild
Journal:  Clin Microbiol Rev       Date:  2004-07       Impact factor: 26.132

7.  Evidence for the presence of a high-affinity laminin receptor-like molecule on the surface of Candida albicans yeast cells.

Authors:  J L López-Ribot; M Casanova; C Monteagudo; P Sepúlveda; J P Martínez
Journal:  Infect Immun       Date:  1994-02       Impact factor: 3.441

8.  Distinct mechanisms of epithelial adhesion for Candida albicans and Candida tropicalis. Identification of the participating ligands and development of inhibitory peptides.

Authors:  C M Bendel; M K Hostetter
Journal:  J Clin Invest       Date:  1993-10       Impact factor: 14.808

Review 9.  The iC3b receptor of Candida albicans and its roles in pathogenesis.

Authors:  Margaret K Hostetter
Journal:  Vaccine       Date:  2008-12-30       Impact factor: 3.641

10.  Antifungals: need to search for a new molecular target.

Authors:  A T Sangamwar; U D Deshpande; S S Pekamwar
Journal:  Indian J Pharm Sci       Date:  2008 Jul-Aug       Impact factor: 0.975

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.